Propafenone and Nebivolol Interaction

Drug interaction information between Propafenone and Nebivolol.

Propafenone and Nebivolol have a documented moderate interaction in FDA labeling.

FDA drug labeling documents a moderate-severity interaction between Propafenone and Nebivolol. This page displays the available source-record category and label text. The category is not an individual risk estimate or medication-combination direction.

Drug A

Propafenone

Class IC Antiarrhythmic

Drug B

Nebivolol

Beta-1 Selective Blocker

How They Interact

Propafenone slows down the body's ability to process nebivolol, which could cause the medication to build up to higher levels.

FDA Label Information

( 7.4 ) 7.1 CYP2D6 Inhibitors Use caution when nebivolol is co-administered with CYP2D6 inhibitors (quinidine, propafenone, fluoxetine, paroxetine, etc.) [ see Clinical Pharmacology ( 12.5 ) ].

Frequently Asked Questions

What SPL severity band is on file for Propafenone + Nebivolol?

Compiled FDA labeling labels this pair moderate. That is a source-record field, not an individual medication-combination decision.

Which drug in this pair has the larger labeled-interaction portfolio?

Propafenone has 26 labeled pairs on file vs Nebivolol's 7. In the moderate band specifically: Propafenone has 3 (also Amiodarone, Fluoxetine); Nebivolol has 2 (also Fluoxetine).

What mechanism field is on file for Propafenone and Nebivolol?

Propafenone slows down the body's ability to process nebivolol, which could cause the medication to build up to higher levels.

Propafenone carries more major-labeled pairs than Nebivolol

SPL source-record counts only. This page's band is moderate · classes on file: Propafenone (Class IC Antiarrhythmic); Nebivolol (Beta-1 Selective Blocker).

Propafenone has 1 major-labeled pair vs Nebivolol's 0. This page itself is in the moderate band, not the major band.

Propafenone

1 major · 3 moderate · 22 minor · 26 total

Nebivolol

0 major · 2 moderate · 5 minor · 7 total

Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. This registry does not provide individual medication-combination directions.